Vanguard Group Inc. Sells 40,189 Shares of Incyte Corporation $INCY

Vanguard Group Inc. reduced its stake in Incyte Corporation (NASDAQ:INCY) by 0.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,911,434 shares of the biopharmaceutical company’s stock after selling 40,189 shares during the period. Vanguard Group Inc. owned 0.10% of Incyte worth $1,966,652,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Munich Reinsurance Co Stock Corp in Munich bought a new position in shares of Incyte in the 4th quarter worth $6,065,000. Rakuten Securities Inc. bought a new position in shares of Incyte in the 4th quarter worth $59,000. Chicago Partners Investment Group LLC boosted its position in shares of Incyte by 6.8% in the 4th quarter. Chicago Partners Investment Group LLC now owns 8,426 shares of the biopharmaceutical company’s stock worth $859,000 after purchasing an additional 538 shares during the last quarter. B. Metzler seel. Sohn & Co. AG boosted its position in shares of Incyte by 46.5% in the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 13,415 shares of the biopharmaceutical company’s stock worth $1,325,000 after purchasing an additional 4,261 shares during the last quarter. Finally, HB Wealth Management LLC boosted its position in shares of Incyte by 7.3% in the 4th quarter. HB Wealth Management LLC now owns 6,082 shares of the biopharmaceutical company’s stock worth $601,000 after purchasing an additional 415 shares during the last quarter. 96.97% of the stock is currently owned by institutional investors.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q1 beat — Incyte reported Q1 EPS and revenue above expectations ($1.81 EPS; $1.27B revenue), driven by Jakafi and Opzelura strength, which supports near-term cash flow and investor confidence. Reuters: Incyte beats first-quarter estimates
• Positive Sentiment: Commercial outlook & launches — Management outlined 2026 net sales guidance in the ~$4.77B–$4.94B range and said it’s preparing four product launches over the next 12 months, indicating multiple growth catalysts beyond the core franchise. Seeking Alpha: Incyte outlines 2026 net sales and launches
• Positive Sentiment: Analyst lift — Stifel raised its price target to $123 and maintained a Buy, providing fresh upside thesis and likely supporting demand for the shares. Benzinga: Stifel raises price target
• Positive Sentiment: Investor outreach — Incyte announced presentations at upcoming investor conferences, which can increase visibility and help clarify commercialization plans. Business Wire: Investor conferences
• Neutral Sentiment: Executive change — Incyte appointed Suketu (Suky) Upadhyay as CFO; leadership continuity matters but is not an immediate earnings driver. Yahoo Finance: CFO appointment
• Neutral Sentiment: Clinical readouts — The company posted Phase 3 vitiligo wins for its JAK inhibitor, but competitive pressure from established rivals (e.g., Rinvoq) leaves market-share outcomes uncertain. FierceBiotech: JAK inhibitor results
• Negative Sentiment: Guidance gap — The company’s 2026 revenue range was below some street estimates (consensus higher), which raises questions about how quickly launches will offset patent/market pressures; this likely tempered upside despite the quarter beat. Seeking Alpha: Guidance and sales outlook
• Negative Sentiment: Regulatory/marketing scrutiny — The FDA criticized past promotional claims around Niktimvo, a reputational and compliance risk that could lead to tighter oversight or remediation costs. FiercePharma: FDA criticism

Insider Activity

In other Incyte news, insider Pablo J. Cagnoni sold 18,667 shares of Incyte stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $96.50, for a total value of $1,801,365.50. Following the sale, the insider owned 262,692 shares of the company’s stock, valued at $25,349,778. This trade represents a 6.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

INCY has been the topic of several recent research reports. UBS Group reduced their price target on Incyte from $104.00 to $94.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 25th. Royal Bank Of Canada dropped their price objective on Incyte from $95.00 to $92.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 11th. Piper Sandler raised their price objective on Incyte from $102.00 to $110.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. TD Cowen reaffirmed a “buy” rating on shares of Incyte in a research note on Tuesday, January 13th. Finally, Morgan Stanley set a $102.00 price objective on Incyte in a research note on Wednesday, February 11th. Ten research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $104.26.

Incyte Stock Performance

Shares of Incyte stock opened at $99.10 on Thursday. The stock’s fifty day simple moving average is $95.84 and its 200 day simple moving average is $98.76. Incyte Corporation has a 12 month low of $57.77 and a 12 month high of $112.29. The company has a market capitalization of $19.72 billion, a PE ratio of 15.46, a PEG ratio of 0.77 and a beta of 0.85. The company has a current ratio of 3.32, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, April 28th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.47. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The firm had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.23 billion. During the same quarter last year, the business posted $1.16 EPS. The company’s revenue for the quarter was up 20.9% on a year-over-year basis. On average, research analysts predict that Incyte Corporation will post 6.46 EPS for the current year.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.